RAPIDe-1, a Phase 2 clinical trial testing Pharvaris’ investigational oral therapy PHVS416 as an on-demand treatment for swelling attacks…
Articles by Marisa Wexler, MS
Treatment with Orladeyo (berotralstat) was generally safe and well-tolerated in people with hereditary angioedema (HAE), according to recently…
Orchard Therapeutics and the Pharming Group are teaming up to research, develop, manufacture, and — possibly — commercialize a…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection), a medication to…
Takhzyro (lanadelumab) is more effective than Cinryze at preventing swelling attacks in people with hereditary angioedema (HAE), a…
Takeda has submitted an application in Japan seeking regulatory approval of Takhzyro (lanadelumab) for the treatment of…
Long-term treatment with the approved therapy Haegarda leads to improved quality of life in people with type 1 or…
People with hereditary angioedema (HAE) would prefer an oral medication that could prevent their attacks, even when satisfied with…
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved oral Orladeyo (berotralstat), at a daily dose of 150 mg,…
Variations in the genes KNG1 and XPNPEP1 may be associated with hereditary angioedema (HAE) that occurs in people without…